US pharmaceutical company Pfizer Inc (NYSE:PFE) has commenced a mid-to-late-stage study testing its investigational oral antiviral drug, PF-07321332, for the prevention of COVID-19 infection among those who have been exposed to the virus, Reuters news agency reported on Monday.
Pfizer said it would study the drug in up to 2,660 healthy adult participants aged 18 and older who live in the same household as an individual with a confirmed symptomatic COVID-19 infection.
The trial will reportedly test PF-07321332 with a low dose of ritonavir, an older medication widely used in combination treatments for HIV infection.
Pfizer had earlier said this month that it had started a mid-to-late-stage trial of PF-07321332 for the treatment of COVID-19 in non-hospitalised, symptomatic adult patients.
Kromek collaborates on next-gen CT detector technology
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring
Henry Schein introduces equipment repair subscription - Henry Schein Thrive Service Plus
Seres Therapeutics provides business updates and reports Q2 2023 financial results